VOR Latest Press Releases

-- October 22, 2026 --

Telitacicept Demonstrates Durable Preservation of Kidney Function Through Two Years in Phase 3 TELIGAN Trial in IgA Nephropathy Globe Newswire 4:05 PM

-- October 5, 2026 --

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 6:00 PM

-- September 29, 2026 --

Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis Globe Newswire 8:05 AM

-- September 8, 2026 --

Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis Globe Newswire 7:00 AM

-- September 4, 2026 --

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- September 1, 2026 --

Vor Bio To Participate in Upcoming September Conferences Globe Newswire 8:00 AM

-- August 11, 2026 --

Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 9:30 AM

-- August 3, 2026 --

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:30 PM

-- July 7, 2026 --

Vor Bio Appoints David Zaccardelli to Board of Directors Globe Newswire 4:01 PM

-- July 2, 2026 --

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 5:30 PM

-- June 8, 2026 --

Telitacicept Receives NMPA Approval for the Treatment of Sjgren's Disease in China Globe Newswire 8:31 AM

Telitacicept Receives NMPA Conditional Approval for the Treatment of IgA Nephropathy in China Globe Newswire 8:30 AM

-- June 1, 2026 --

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 5:00 PM

-- May 28, 2026 --

Vor Bio to Participate in the 2026 Jefferies Global Healthcare Conference Globe Newswire 8:30 AM

Market Data Delayed 15 Minutes